Aktiv Pharma Group Receives Grant Funding to Develop Tranexamic Acid Autoinjector
Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding.
Uncontrolled bleeding is the number one cause of death on the battlefield and pre-hospital treatment options prior to evacuation to definitive care are limited [2]. Furthermore, it is estimated that 18,400 preventable deaths occur each year in the U.S. alone due to hemorrhage after injury [3]. “We are proud to develop a product that will be available for the U.S. Warfighter and emergency medical responders to treat patients in the field as close as possible to the time of injury, with an autoinjector that meets and exceeds the most stringent reliability requirements of the U.S. Food and Drug Administration (FDA) for emergency-use injectors”.
The ARAI autoinjector has been developed by Aktiv with the support of the DOD and the U.S. Department of Health and Human Services (HHS) Biotechnology Advanced Research and Development Authority (BARDA) as a next generation autoinjector platform to address the shortfalls of previous autoinjectors, by improving usability, reliability, robustness, and drug stability. ARAI is a versatile platform that can deliver up to 5 ml dose volumes, perform simultaneous injections of multiple, separately stored drug formulations, and automatically reconstitute drugs formulated in dry form. Aktiv is currently expanding the ARAI platform to include a consumer market autoinjector for biopharmaceuticals that will feature the same reliability, robustness, and usability benefits in a smaller form factor and with added data connectivity.
Aktiv is leveraging its superior autoinjector technology to advance the strongest emergency treatment pipeline in the industry, which currently includes atropine, pralidoxime chloride (2-PAM), atropine/2-PAM dual-injection, and scopolamine in development as a treatment for nerve agent poisoning, and is planning to add at least one more emergency treatment to its pipeline by 2023. Aktiv is also collaborating with another pharmaceutical company to develop a reconstitution autoinjector for a long-acting formulation of naloxone. “We are humbled by the opportunities entrusted to us by the U.S. Government to help save lives from trauma injuries, to protect our military and the homeland from unconventional weapon threats, and to improve our response to mass casualty events”, Mr. Genosar added.
About Aktiv
Aktiv is a vertically integrated specialty pharmaceutical company with combination product contract development and manufacturing organization (CDMO) capabilities, developing, manufacturing, and commercializing sterile injectable products in a portfolio of proprietary, value-added, glass-free prefilled delivery systems. Aktiv’s has unique combination product competencies, specifically targeting biopharmaceuticals. The company’s facilities in Colorado include device development, chemistry, manufacturing and controls (CMC), and manufacturing equipment labs, assembly rooms operated under Good Manufacturing Practice (GMP), and sterile fill-finish suites. Aktiv can be reached at https://aktivpharmagroup.com/contact.
[1] The funding is provided by the Office of the Assistant Secretary of Defense for Health Affairs, through the U.S. Army Medical Research and Development Command under Award No. W81XWH-22-1-0225. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. In conducting research using animals, the investigator(s) adheres to the laws of the United States and regulations of the Department of Agriculture.
[2] Eastridge, Brian J et al. “Outcomes of traumatic hemorrhagic shock and the epidemiology of preventable death from injury.” Transfusion vol. 59,S2 (2019): 1423-1428.
[3] Spinella, Philip Charles. “Zero preventable deaths after traumatic injury: An achievable goal.” The journal of trauma and acute care surgery vol. 82,6S Suppl 1 (2017): S2-S8.
Related news
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful first implant of the Company’s...
-
7-year-old Boy Managing His Hydrocephalus with ReFlow Ventricular System “Gen 1” Featured on Charleston’s ABC News 4
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of cerebrospinal fluid in the brain that affects more than one million Americans.
-
NICE Irreversible Electroporation for Treating Prostate Cancer Announcement
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute for Health and Care Excellence (NICE) Interventional Procedures Advisory Committee (IPAC) upgraded the guidance for...
-
Best HIFU ultrasound facelift machine for medical aesthetic
Today, the medical aesthetic industry has developed to make people more comfortable and safe in their pursuit of beauty. Among the many medical aesthetic procedures available, the best HIFU machine professional is a popular one. It is based on high intensity focused ultrasound technology and provides amazing aesthetic results. This article will reveal the magic of HIFU in a number of sections. Bvlaser is a ODM face lift HIFU machine manufacturer, we have HIFU vaginal tightening machine for sale. Principles of...
-
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 countries Study will add to the robust development program for aflibercept 8 mg, exploring the potential to achieve visual...
Customer comments
No comments were found for Aktiv Pharma Group Receives Grant Funding to Develop Tranexamic Acid Autoinjector. Be the first to comment!